Blood, meat, and upscaling tissue engineering: Promises, anticipated markets, and performativity in the biomedical and agri-food sectors.

Tissue engineering is a set of biomedical technologies, including stem cell science, which seek to grow biological tissue for a diversity of applications. In this paper, we explore two emergent tissue engineering technologies that seek to cause a step change in the upscaling capacity of cell growth: cultured blood and cultured meat. Cultured blood technology seeks to replace blood transfusion with a safe and affordable bioengineered replacement. Cultured meat technology seeks to replace livestock-based food production with meat produced in a bioreactor. Importantly, cultured meat technology straddles the industrial contexts of biomedicine and agrifood. In this paper, we articulate (i) the shared and divergent promissory trajectories of the two technologies and (ii) the anticipated market, consumer, and regulatory contexts of each. Our analysis concludes by discussing how the sectoral ontologies of biomedicine and agri-food impact the performative capacity of each technology's promissory trajectory.